Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
39.52 (1y: +1%)
Market Cap 1.08 B P/E(ttm)
Enterprise Value 777.16 M P/B 4.70
GEVA- NAS (USA)
Synageva BioPharma Corp
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$39.52
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt No Debt
GEVA's Cash to Debt is ranked higher than
88% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GEVA: No Debt )
GEVA' s 10-Year Cash to Debt Range
Min: 24.86   Max: No Debt
Current: No Debt
Equity to Asset 0.888
GEVA's Equity to Asset is ranked higher than
90% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. GEVA: 0.888 )
GEVA' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.93
Current: 0.89
0.37
0.93
Interest Coverage No Debt
GEVA's Interest Coverage is ranked lower than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GEVA: No Debt )
GEVA' s 10-Year Interest Coverage Range
Min: 355   Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 61.34
M-Score: -4.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -287.70
GEVA's Operating margin (%) is ranked lower than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. GEVA: -287.70 )
GEVA' s 10-Year Operating margin (%) Range
Min: -6866.7   Max: 120.8
Current: -287.7
-6866.7
120.8
Net-margin (%) -287.2
GEVA's Net-margin (%) is ranked lower than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. GEVA: -287.2 )
GEVA' s 10-Year Net-margin (%) Range
Min: -6679.4   Max: 81
Current: -287.2
-6679.4
81
ROE (%) -18.7
GEVA's ROE (%) is ranked higher than
58% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. GEVA: -18.7 )
GEVA' s 10-Year ROE (%) Range
Min: -132.1   Max: 40.7
Current: -18.7
-132.1
40.7
ROA (%) -17.7
GEVA's ROA (%) is ranked higher than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. GEVA: -17.7 )
GEVA' s 10-Year ROA (%) Range
Min: -82.8   Max: 34.8
Current: -17.7
-82.8
34.8
Revenue Growth (%) -33.6
GEVA's Revenue Growth (%) is ranked higher than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. GEVA: -33.6 )
GEVA' s 10-Year Revenue Growth (%) Range
Min: -48.2   Max: 70
Current: -33.6
-48.2
70
ยป GEVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

GEVA Guru Trades in Q2 2012

Jim Simons 259,620 sh (New)
Steven Cohen 6,488 sh (New)
Columbia Wanger 877,000 sh (New)
» More
Q3 2012

GEVA Guru Trades in Q3 2012

Columbia Wanger 1,152,000 sh (+31.36%)
Steven Cohen Sold Out
Jim Simons 190,920 sh (-26.46%)
» More
Q4 2012

GEVA Guru Trades in Q4 2012

Columbia Wanger 1,660,214 sh (+44.12%)
Jim Simons 142,820 sh (-25.19%)
» More
Q1 2013

GEVA Guru Trades in Q1 2013

Columbia Wanger 1,927,289 sh (+16.09%)
Jim Simons 46,901 sh (-67.16%)
» More
» Details

Insider Trades

Latest Guru Trades with GEVA



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 4.70
GEVA's P/B is ranked lower than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. GEVA: 4.70 )
GEVA' s 10-Year P/B Range
Min: 0.76   Max: 22.64
Current: 4.7
0.76
22.64
P/S 53.60
GEVA's P/S is ranked lower than
84% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. GEVA: 53.60 )
GEVA' s 10-Year P/S Range
Min: 0.99   Max: 1141.67
Current: 53.6
0.99
1141.67
EV-to-EBIT 1.7
GEVA's EV-to-EBIT is ranked higher than
91% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. GEVA: 1.7 )
GEVA' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 111.3
Current: 1.7
0.1
111.3
Shiller P/E 71
GEVA's Shiller P/E is ranked higher than
83% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. GEVA: 71 )
GEVA' s 10-Year Shiller P/E Range
Min: 2.87   Max: 551.67
Current: 71
2.87
551.67

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 5.1
GEVA's Price/Net Cash is ranked higher than
77% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. GEVA: 5.1 )
GEVA' s 10-Year Price/Net Cash Range
Min: 1.3   Max: 221
Current: 5.1
1.3
221
Price/Net Current Asset Value 94.6
GEVA's Price/Net Current Asset Value is ranked higher than
87% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. GEVA: 94.6 )
GEVA' s 10-Year Price/Net Current Asset Value Range
Min: 4   Max: 94.5
Current: 94.6
4
94.5
Price/Tangible Book 4.9
GEVA's Price/Tangible Book is ranked higher than
73% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. GEVA: 4.9 )
GEVA' s 10-Year Price/Tangible Book Range
Min: 1   Max: 14.6
Current: 4.9
1
14.6
Price/DCF (Projected) 4.7
GEVA's Price/DCF (Projected) is ranked higher than
97% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. GEVA: 4.7 )
GEVA' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 6.2
Current: 4.7
0.4
6.2
Price/Median PS Value 2.4
GEVA's Price/Median PS Value is ranked higher than
98% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. GEVA: 2.4 )
GEVA' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 41.3
Current: 2.4
0.1
41.3
Earnings Yield (Greenblatt) 57.60
GEVA's Earnings Yield (Greenblatt) is ranked higher than
91% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. GEVA: 57.60 )
GEVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 3695.6
Current: 57.6
0.9
3695.6
Forward Rate of Return (Yacktman) 0.93
GEVA's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. GEVA: 0.93 )
GEVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -64.2   Max: 49.2
Current: 0.93
-64.2
49.2

Business Description

Synageva BioPharma is a clinical stage biopharmaceutical company incorporated in 1993. It is focused on the discovery, development and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical needs. The Company has several protein therapeutic in its pipeline, including two enzyme replacement therapies for lysosomal storage disorders and two additional programs for other life-threatening genetic conditions for which there are currently no approved treatments. It has assembled a team with a proven record of bringing orphan therapies to patients. The Company's lead program, SBC-102 is an enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a lysosomal storage disorder (LSD). The product is a recombinant form of the human LAL enzyme. This enzyme is responsible for the metabolism of cholesteryl esters and triglycerides that are delivered to lysosomes by a variety of routes including low-density lipoprotein (LDL) receptor mediated endocytosis. SBC-102 contains glycan structures that are specifically recognized and internalized by specific receptors into key target cells. In addition to SBC-102, Synageva has several other protein therapeutic programs targeting rare diseases in various stages of preclinical development. These include enzyme replacement therapies for other lysosomal storage disorders as well as programs for rare, life-threatening conditions beyond the lysosomal storage disorders. These protein therapeutic programs were selected based on scientific rationale, unmet medical need, potential to impact disease course and strategic alignment with Synageva's corporate focus. These pipeline programs (SBC-103, SBC-104, SBC-105, and SBC-106) have the potential to offer patients and health care providers effective therapies to treat the rare and devastating diseases targeted by these programs. The Company is currently developing marketing, sales and distribution capabilities to support commercialization for SBC-102. Its current plans for commercialization resources include limited field-based representatives supported by a specialized in-house organization to address the needs and opportunities for the North American, European, Latin American, and Asia Pacific regions. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The Company is subject to extensive regulation by governmental authorities in the U.S. and other countries.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:TMS1.Germany
ยป More Articles for GEVA

Headlines

Articles On GuruFocus.com


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial